Dimethyl fumarate controlled-release - Forward Pharma

Drug Profile

Dimethyl fumarate controlled-release - Forward Pharma

Alternative Names: FP-187

Latest Information Update: 09 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Forward Pharma
  • Developer Forward Pharma; Skane University Hospital
  • Class Anti-inflammatories; Antipsoriatics; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Plaque psoriasis; Psoriatic arthritis
  • Preclinical Multiple sclerosis

Most Recent Events

  • 07 May 2018 Forward Pharma files a notice of appeal with European Patent Organisation for EP 2 801 355 patent covering dimethyl fumarate controlled release formulation
  • 22 Mar 2018 Forward pharma receives reasons for the decision of the European Patent Office in the Opposition Proceedings for the EP 2 801 355 patent
  • 29 Jan 2018 European Patent Office revokes EP 2 801 355 patent following the oral hearing in the opposition proceedings
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top